Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12858755 | 0.87 | LMNA (0.41) | LMNAMAPK1TSHRKDM4EL3MBTL1 | |
| SCHEMBL13875719 | 0.85 | KMT2A (0.43) | LMNAMAPK1TSHRKDM4EADRA2A | |
| SCHEMBL8029351 | 0.85 | KMT2A (0.43) | LMNAMAPK1TSHRKDM4EADRA2A | |
| SCHEMBL1094149 | 0.82 | LMNA (0.46) | LMNAMAPK1TSHRKDM4EL3MBTL1 | |
| SCHEMBL16920301 | 0.78 | KMT2A (0.46) | LMNAMAPK1TSHRKDM4EADRA2A | |
| SCHEMBL8923168 | 0.78 | LMNA (0.44) | LMNAMAPK1TSHRKDM4EL3MBTL1 | |
| SCHEMBL619133 | 0.78 | KMT2A (0.46) | LMNAMAPK1TSHRKDM4EADRA2A | |
| SCHEMBL16920295 | 0.78 | KMT2A (0.46) | LMNAMAPK1TSHRKDM4EADRA2A | |
| SCHEMBL18866336 | 0.76 | LMNA (0.59) | LMNAMAPK1TSHRL3MBTL1F2 | |
| SCHEMBL194418 | 0.76 | SLC6A4 (0.41) | LMNAMAPK1TSHRKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034184-B2 | Process for producing azine compounds and oxime compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-04-25 | — | — | US | disclosed |
| EP-1342714-B1 | Process for producing azine compounds and oxime compounds | DAICEL CHEM (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-20030204084-A1 | Process for producing azine compounds and oxime compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1342714-A1 | Process for producing azine compounds and oxime compounds | Daicel Chemical Industries, Ltd. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204084-A1 | Process for producing azine compounds and oxime compounds | CBR1, DAO, ALKBH2 | LMNA 3050/4885MAPK1 1839/4885TSHR 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.